Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With An Import Alert, India's Aurobindo Reels Under U.S. FDA Glare; Four Pfizer Products Impacted

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - In what is being described as a body blow to the reputation of Indian drug companies, U.S. FDA imposed an import alert against one manufacturing site of Aurobindo Pharma located near the central Indian city of Hyderabad

You may also be interested in...



With Seroquel Generic Approval, Is Aurobindo Close To Getting Off The FDA Hook?

India’s Aurobindo Pharma lands U.S. FDA approval of generic Seroquel despite warning letter issued last year.

Ranbaxy Forecasts Conservative Growth, Remains Silent On Atorvastatin Launch, U.S. FDA Action

MUMBAI - Daiichi-Sankyo controlled Ranbaxy Laboratories Ltd. took analysts in India by surprise with a forecast of a very conservative growth target that did not factor in any upside from a possible launch of a generic version of Lipitor (atorvastatin) in the U.S

As Pfizer Deal Speeds Up, Aurobindo Tangos With AstraZeneca For Branded Generics Play In Emerging Markets

MUMBAI - India's Aurobindo Pharma is turning out to be a partner of choice for Big Pharma companies that intend to dig aggressively into emerging markets with a branded generics product portfolio

Related Content

UsernamePublicRestriction

Register

SC077227

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel